0.61

4.31% 0.0252

After Hours: .61

Vivos Therapeutics Inc (VVOS)

Overview News Price History Financials Discussions Forecast Stock Split

Vivos Therapeutics Inc stock is traded at $0.61, with a volume of 143.71K. It is up +4.31% in the last 24 hours and down -40.78% over the past month. Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Previous Close:

$0.5848

Open:

$0.599

24h Volume:

143.71K

Relative Volume:

0.68

Market Cap:

$8.48M

Revenue:

$17.44M

Net Income/Loss:

$-21.23M

P/E Ratio:

-0.2728

EPS:

-2.2361

Net Cash Flow:

$-17.60M

1W Performance:

-4.84%

1M Performance:

-40.78%

6M Performance:

-72.27%

1Y Performance:

-70.81%

1-Day Range:

$0.599

$0.6614

1-Week Range:

$0.545

$0.6614

52-Week Range:

$0.545

$7.95

Vivos Therapeutics Inc Stock (VVOS) Company Profile

Name

Vivos Therapeutics Inc

Sector

Healthcare (1108)

Industry

Medical Devices (143)

Phone

(866)908-4867

Address

7921 SOUTHPARK PLAZA,, LITTLETON

Employee

268

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

VVOS's Discussions on Twitter

Compare VVOS vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VVOS Vivos Therapeutics Inc	0.61	8.13M	17.44M	-21.23M	-17.60M	-2.2361
ABT Abbott Laboratories	87.41	152.88B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	316.48	120.18B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	78.60	100.34B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	57.78	84.95B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	85.78	47.91B	6.30B	1.07B	1.09B	1.8406

Vivos Therapeutics Inc Stock (VVOS) Latest News

May 22, 2026

Vivos Therapeutics Balances Rapid Growth With Cash Strain - TipRanks

May 22, 2026

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q1 2026 Earnings Call Transcript - Insider Monkey

May 22, 2026

May 21, 2026

Vivos Therapeutics Earnings Call: Growth Meets Cash Strain - TipRanks

May 21, 2026

May 20, 2026

Vivos Therapeutics, Inc. 1Q 2026: Revenue $5.14M, EPS $(0.52) — 10-Q Summary - TradingView

May 20, 2026

Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 20, 2026

Vivos Therapeutics (NASDAQ: VVOS) Q1 2026 loss and going concern risk - Stock Titan

May 20, 2026

Vivos Therapeutics reports 70% revenue increase in Q1 2026 - Investing.com

May 20, 2026

Vivos Therapeutics reports 70% revenue increase in Q1 2026 By Investing.com - Investing.com Canada

May 20, 2026

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - The Manila Times

May 20, 2026

BRIEF-Vivos Therapeutics Q1 Net Income USD -7.751 Million - TradingView

May 20, 2026

Press Release: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update - Moomoo

May 20, 2026

VVOS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

May 20, 2026

May 15, 2026

Vivos Therapeutics Delays Quarterly Filing - TipRanks

May 15, 2026

Vivos Therapeutics (VVOS) delays Q1 10-Q; preliminary revenue up ~70% - Stock Titan

May 15, 2026

Armistice Capital (NASDAQ: VVOS) reports 8.27% holding in Vivos Therapeutics - Stock Titan

May 15, 2026

Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential - MSN

May 10, 2026

Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges - TipRanks

May 10, 2026

May 08, 2026

3.96M warrant shares registered by Vivos (VVOS) for resale; $2.09 strike - Stock Titan

May 08, 2026

May 05, 2026

VVOS Forecast, Price Target & Analyst Ratings | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill

May 05, 2026

Apr 30, 2026

Vivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47 - MSN

Apr 30, 2026

Apr 29, 2026

Broadcom, Vivos Therapeutics and 3 stocks to watch heading into Monday - MSN

Apr 29, 2026

Vivos Therapeutics (NASDAQ: VVOS) registers 3.96M warrant-linked shares for resale - Stock Titan

Apr 29, 2026

Apr 24, 2026

VVOS Should I Buy - Intellectia AI

Apr 24, 2026

Apr 22, 2026

Vivos Therapeutics receives Nasdaq notice for stockholders’ equity deficiency - Investing.com

Apr 22, 2026

Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Apr 22, 2026

Equity shortfall puts Vivos Therapeutics (NASDAQ: VVOS) at Nasdaq delisting risk - Stock Titan

Apr 22, 2026

Qorvo To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

Apr 22, 2026

Apr 21, 2026

Vivos Reports 16% Revenue Increase in 2025 Following Business Model Shift - Sleep Review

Apr 21, 2026

Apr 20, 2026

Vivos Therapeutics stock price target lowered to $2.50 by H.C. Wainwright - Investing.com Australia

Apr 20, 2026

Apr 18, 2026

New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM ESTShow #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Viv - ACCESS Newswire

Apr 18, 2026

Apr 17, 2026

H.C. Wainwright Maintains Vivos Therapeutics(VVOS.US) With Buy Rating, Cuts Target Price to $2.5 - 富途牛牛

Apr 17, 2026

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call Transcript - Insider Monkey

Apr 17, 2026

Apr 16, 2026

Vivos Therapeutics (VVOS) Stock: Why Cash Position (Freefalls) 2026-04-16Trending Entry Points - UBND thành phố Hải Phòng

Apr 16, 2026

Vivos Therapeutics Balances Growth Hopes With Cash Strain - TipRanks

Apr 16, 2026

Vivos Therapeutics Reports Full Year 2025 Financial Results - ADVFN

Apr 16, 2026